
Cambrian BioPharma
Cambrian Biopharma: A DisCo advancing modern healthcare with breakthrough medicines to enhance healthspan and quality of life.
- 30
- Company
- New York, NY, USUnited States
Cambrian Biopharma is a clinical-stage drug development company focused on modernizing healthcare by creating therapeutics that extend healthspan, the period of life spent in good health. As a Distributed Development Company (DisCo), Cambrian advances multiple scientific breakthroughs targeting biological drivers of aging. Their approach involves developing interventions to treat specific diseases first, then deploying them as preventative medicines to enhance overall quality of life.
Cambrian Biopharma has partnered with exceptional scientists to harness advancements in aging biology, aiming to redefine healthcare by treating and ultimately preventing chronic diseases. The company has made significant progress in understanding mechanisms that change with age, positioning itself as a leader in developing future medicines.
Similar Companies
Dice Therapeutics

Orna Therapeutics

Ajax Therapeutics

Sail Biomedicines
Forte Biosciences

Rejuveron Life Sciences
rejuveron.com

Retro Biosciences
retro.bio

Juvenescence
juvlabs.com

Oisin Biotechnologies
oisinbio.com

Continuum Biosciences

Regenerative Bio
regen-bio.us

Generian Pharmaceuticals
generian.com

Spring Discovery

Rubedo Life Sciences
rubedolife.com

HCW Biologics
hcwbiologics.com

Transcera
transcera.bio

Underdog Pharmaceuticals
cyclaritytx.com

TenSixteen Bio

Repair Biotechnologies

BioAge Labs
bioagelabs.com

New Frontier Bio
newfrontierbio.com
Quick Facts
Who are Cambrian BioPharma's competitors?
Companies similar to Cambrian BioPharma include Dice Therapeutics, Orna Therapeutics, Sail Biomedicines and Forte Biosciences.
When was Cambrian BioPharma founded?
Cambrian BioPharma was founded in 2019.
Where is Cambrian BioPharma's headquarters located?
Cambrian BioPharma's headquarters is located in New York, NY, US.
When was Cambrian BioPharma's last funding round?
Cambrian BioPharma's most recent funding round was for $123.8M (USD) in June 2026.
How much disclosed funding has Cambrian BioPharma raised?
As of Jun 30, 2026, Cambrian BioPharma has disclosed funding of $283.8M (USD). Undisclosed round amounts are excluded.
How many employees does Cambrian BioPharma have?
Cambrian BioPharma has 30 employees as of Feb 5, 2024.
Classification
- Industry
- Ownership
- Technology
- Geographic Exposure
- Customer
- Main Product
- Tags
- Also Known As
- Cambrian BioPharma Inc
- Headquarters
- 228 Park Avenue South
- Suite 66643
- New York, NY, 10003
- US
- SEC CIK
- 0001797409
- EIN
- 84-2985609
- NAICS
- 540000Professional, Scientific, and Technical Services
- 541714Research and Development in Biotechnology (except Nanobiotechnology)
- 541000Professional, Scientific, and Technical Services
- 541700Scientific Research and Development Services
- 541710Research and Development in the Physical, Engineering, and Life Sciences
- SIC
- 8700Engineering, Accounting, Research, Management, And Related Services
- 8730Research, Development, And Testing Services
- 8731Commercial Physical and Biological Research
- Industry
- —Biotechnology Companies
- —Health Care Companies
- —Medical Organizations
- —Pharmaceutical Companies
Show 13 more industry codes
- NAICS
- 320000Manufacturing
- 325400Pharmaceutical and Medicine Manufacturing
- 620000Health Care and Social Assistance
- 325000Chemical Manufacturing
- 623000Nursing and Residential Care Facilities
- 325410Pharmaceutical and Medicine Manufacturing
- 325412Pharmaceutical Preparation Manufacturing
- SIC
- 2800Chemicals And Allied Products
- 8000Health Services
- 2830Drugs
- 8040Offices And Clinics Of Other Health Practitioners
- 2834Pharmaceutical Preparations
- 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified